Treatment of Chronic Cervical-Associated Headache With Botulinum Toxin A: A Pilot Study
Autor: | Marvin Schwartz, Brian Freund |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
Male medicine.medical_specialty Tension headache Headache Disorders Visual analogue scale medicine.medical_treatment Pilot Projects Neurological disorder Double-Blind Method Cervicogenic headache medicine Humans Botulinum Toxins Type A Range of Motion Articular Saline Aged Pain Measurement business.industry Headache Middle Aged medicine.disease Botulinum toxin Surgery Muscle relaxation Neuromuscular Agents Neurology Anesthesia Chronic Disease Female Neurology (clinical) Range of motion business Neck medicine.drug |
Zdroj: | Headache: The Journal of Head and Face Pain. 40:231-236 |
ISSN: | 1526-4610 0017-8748 |
Popis: | Objective.–To see whether therapy with botulinum toxin A may prove to be an effective treatment for headache of musculoskeletal origin. Background.–Headache is a common finding associated with neck injury. Cervicogenic headache, which is believed to be attributable to injury of the ligaments, muscles, or joints of the cervical spine, is centered in the occipital region with pain referred to the frontotemporal region. Botulinum toxin A produces prolonged muscle relaxation, which is dose dependent and can be easily targeted to affected muscles. Methods.–This randomized, double-blind, placebo-controlled study compares outcome measures in 26 patients suffering from chronic headache subsequent to a cervical whiplash injury. One half of the patients received botulinum toxin A, 100 units, diluted in 1 mL of saline, while the other half received just saline (1 mL). Five cervical trigger points received 0.2 mL each of injectant via a 30-gauge needle. Outcome measures included subjective head pain based on visual analog scales, as well as range of neck motion. Follow-up assessments were carried out at 2 and 4 weeks after treatment. Results.–Fourteen subjects who received botulinum toxin A and 12 who received saline completed the study. At both 2 and 4 weeks post injection, the treatment group showed a significant improvement in pain and range of motion from preinjection levels (P |
Databáze: | OpenAIRE |
Externí odkaz: |